Fiche centre
Xenoscience
Phoenix — United States
Essais liés8clinical trials
VillePhoenixlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04770220
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| SPN-817 | Épilepsie | Phase 2 | NCT06798896 | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures | RECRUITING |
| Experimental: ALZ-801 | Alzheimer | Phase 3 | NCT04770220 | APOLLOE4 — An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects | COMPLETED |
| TAK-935 | Épilepsie | Phase 1/2 | NCT03166215 | Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies | COMPLETED |
| Vagus Nerve Stimulation Therapy | SEP | Phase 4 | NCT00215215 | Effectiveness Study Comparing Treatment With Drug(s) or Adjunctive VNS Therapy for Pharmacoresistant Partial Seizures | TERMINATED |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05667142 | X-ACKT — A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05718817 | X-TOLE4 — An Open-label Study of XEN1101 in Epilepsy | ENROLLING_BY_INVITATION |
| Fenebrutinib | SEP | Phase 3 | NCT04586023 | FENhance 2 — Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |